ArticleInvestigative ophthalmology & visual science2025
Corneal Myofibroblasts Suppress T-Cell Immunity in Corneal Transplantation.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Purpose: To evaluate the immunoregulatory effect of corneal myofibroblasts on effector T cells derived from allogeneic corneal transplant recipient mice. Methods: Allo-primed CD4+CD25- effector T cells isolated from the draining lymph nodes of corneal transplant recipient mice were cocultured with corneal myofibroblasts or corneal fibroblasts. Flow cytometry was used to measure effector T-cell activation and function by expression of CD69, CD40L, and IFN-γ. Flow cytometry was also used to quantify T-cell apoptosis and T-cell proliferation upon coculture with corneal myofibroblasts. Results: Coculturing effector T cells with corneal myofibroblasts led to a significant decrease in effector T-cell activation as assessed by T-cell expression of CD69 (5520 ± 373 vs. 1701 ± 140) and CD40L (127.50 ± 4.17 vs. 42.87 ± 2.63) mean fluorescence intensity; this suppression was not seen with corneal fibroblasts. Coculture of T cells with myofibroblasts additionally led to a significant reduction in the frequency of IFN-γ+ effector T cells compared to coculture with fibroblasts (2.94% ± 0.85% vs. 0.65% ± 0.23%). Finally, compared to fibroblasts, coculture with myofibroblasts led to a significant increase in the frequency of apoptotic effector T cells (14.78% ± 3.67% vs. 32.48% ± 5.43%) and a significant reduction in T-cell proliferation (61.60% ± 2.68% vs. 39.63% ± 0.92%). Conclusions: Myofibroblasts are capable of suppressing T-cell immunity through suppression of effector T-cell proliferation, activation, and function, as well as the promotion of T-cell apoptosis. Our data suggest that in addition to their well-established role in extracellular matrix production, myofibroblasts may also actively participate in immunoregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.